VEGFA gene locus analysis across 80 human tumour types reveals gene amplification in several neoplastic entities

Angiogenesis

Volumn 17, Issue 3, 2014, Pages 519-527

  Andreozzi, Mariacarla ^a   Quagliata, Luca ^a   Gsponer, Joel R ^a   Ruiz, Christian ^a   Vuaroqueaux, Vincent ^b   Eppenberger Castori, Serenella ^a   Tornillo, Luigi ^a   Terracciano, Luigi M ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b CHARLES RIVER LABORATORIES   (United States)

Author keywords

6p12; FISH; Gene amplification; TMA; VEGFA

Indexed keywords

VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL CARCINOMA; GENE AMPLIFICATION; GENE LOCUS; GENE MUTATION; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LARGE CELL CARCINOMA; LIVER CELL CARCINOMA; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; TISSUE MICROARRAY; VEGFA GENE; ANIMAL; CHROMOSOME 6; CLASSIFICATION; DRUG SCREENING; GENETICS; MICROVASCULATURE; NEOPLASM; NUDE MOUSE; PATHOLOGY;

ANIMALS; CHROMOSOMES, HUMAN, PAIR 6; COMPARATIVE GENOMIC HYBRIDIZATION; GENE AMPLIFICATION; GENETIC LOCI; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MICE; MICE, NUDE; MICROVESSELS; NEOPLASMS; TISSUE ARRAY ANALYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84902070174     PISSN: 09696970     EISSN: 15737209     Source Type: Journal    
DOI: 10.1007/s10456-013-9396-z     Document Type: Article

References (32)

1. Ellis LM, Hicklin DJ (2008) VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 8:579-591
2. Eppenberger U, Kueng W, Schlaeppi JM, Roesel JL, Benz C, Mueller H et al (1998) Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients. JCO 16:3129-3136
3. Hubbard J, Grothey A (2010) Antiangiogenesis agents in colorectal cancer. Curr Opin Oncol 22:374-380
4. Fan F, Samuel S, Gaur P, Lu J, Dallas NA, Xia L et al (2011) Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration. Br J Cancer 104:1270-1277
5. Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3:401-410
6. Vlajnic T, Andreozzi MC, Schneider S, Tornillo L, Karamitopoulou E, Lugli A et al (2011) VEGFA gene locus (6p12) amplification identifies a small but highly aggressive subgroup of colorectal cancer [corrected] patients. Mod Pathol 24:1404-1412
7. Schneider BP, Gray RJ, Radovich M, Shen F, Vance G, Li L et al (2013) Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial. Clin Cancer Res 19:1281-1289
8. Baumhoer D, Tornillo L, Stadlmann S, Roncalli M, Diamantis EK, Terracciano LM (2008) Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples. Am J Clin Pathol 129:899-906
9. Heaphy CM, Subhawong AP, Hong SM, Goggins MG, Montgomery EA, Gabrielson E et al (2011) Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol 179:1608-1615
10. Sauter G, Moch H, Carroll P, Kerschmann R, Mihatsch MJ, Waldman FM (1995) Chromosome-9 loss detected by fluorescence in situ hybridization in bladder cancer. IJC 64:99-103
11. Wolff AC, Hammond M, Schwartz JN et al (2007) American society of clinical oncology/college of american pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. JCO 25:118-145
12. Salido M, Tusquets I, Corominas JM, Suarez M, Espinet B, Corzo C et al (2005) Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry. BCR 7:R267-R273
13. Torrisi R, Rotmensz N, Bagnardi V, Viale G, Curto BD, Dell'orto P et al (2007) HER2 status in early breast cancer: relevance of cell staining patterns, gene amplification and polysomy 17. Eur J Cancer 43:2339-2344
14. Tapia C, Savic S, Wagner U, Schonegg R, Novotny H, Grilli B et al (2007) HER2 gene status in primary breast cancers and matched distant metastases. BCR 9:R31
15. Ma Y, Lespagnard L, Durbecq V, Paesmans M, Desmedt C, Gomez-Galdon M et al (2005) Polysomy 17 in HER-2/neu status elaboration in breast cancer: effect on daily practice. Clin Cancer Res 11:4393-4399
16. Team RC (2012) A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria ISBN 3-900051-07-0, URL http://cran.case.edu/web/packages/dplR/vignettes/timeseries-dplR.pdf
17. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S et al (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5:R80
18. Mike L, Smith JCM, Steven McKinney, Thomas Hardcastle and Natalie P (2009) Thorne snapCGH: Segmentation, normalisation and processing of aCGH data. R package version 1280
19. Olshen AB, Venkatraman ES, Lucito R, Wigler M (2004) Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 5:557-572
20. Olshen. VESaA. DNAcopy: DNA copy number data analysis. R package version 1320
21. Santos GC, Zielenska M, Prasad M, Squire JA (2007) Chromosome 6p amplification and cancer progression. J Clin Pathol 60:1-7
22. Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P, Minguez B et al (2008) Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res 68:6779-6788
23. Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhim R et al (2007) Characterizing the cancer genome in lung adenocarcinoma. Nature 450:893-898
24. Knuutila S, Bjorkqvist AM, Autio K, Tarkkanen M, Wolf M, Monni O et al (1998) DNA copy number amplifications in human neoplasms: review of comparative genomic hybridization studies. Am J Pathol 152:1107-1123
25. Yoon HH, Shi Q, Sukov WR, Lewis MA, Sattler CA, Wiktor AE et al (2012) Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma. JCO 30:3932-3938
26. Tse CH, Hwang HC, Goldstein LC, Kandalaft PL, Wiley JC, Kussick SJ et al (2011) Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy. JCO 29:4168-4174
27. Ley TJ et al (2013) Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 368:2059-2074
28. Barretina J, Taylor BS, Banerji S, Ramos AH, Lagos-Quintana M, Decarolis PL et al (2010) Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet 42:715-721
29. Nagano A, Ohno T, Shimizu K, Hara A, Yamamoto T, Kawai G et al (2010) EWS/Fli-1 chimeric fusion gene upregulates vascular endothelial growth factor-A. IJC 126:2790-2798
30. Kreuter M, Paulussen M, Boeckeler J, Gerss J, Buerger H, Liebscher C et al (2006) Clinical significance of Vascular Endothelial Growth Factor-A expression in Ewing's sarcoma. Eur J Cancer 42:1904-1911
31. Yang J, Yang D, Sun Y, Sun B, Wang G, Trent JC et al (2011) Genetic amplification of the vascular endothelial growth factor (VEGF) pathway genes, including VEGFA, in human osteosarcoma. Cancer 117:4925-4938
32. Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D et al (2011) Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 91:1071-1121